Zobrazeno 1 - 10
of 35
pro vyhledávání: '"35"'
Autor:
Ramona F. Swaby, Barbara Burtness, Lisa Licitra, Makoto Tahara, Jean-Pascal Machiels, Ezra E.W. Cohen, Danny Rischin, Lillian L. Siu, Cecilia Pinheiro, Kevin J. Harrington, Ying Zhu, Chooi Peng Lee
Publikováno v:
Journal of Clinical Oncology. 38:TPS6589-TPS6589
TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of pembrolizumab plus
Autor:
Kate Fitch, Scott C. Flanders, Michael T. Schweizer, Rana R. McKay, Christine Ferro, Michael D. Fabrizio
Publikováno v:
Journal of Clinical Oncology. 38:42-42
42 Background: Since the mCRPC treatment landscape is evolving, we examined real-world use and outcomes of sipuleucel-T (sip-T) and oral agents (abiraterone acetate and enzalutamide) in men with mCRPC. Methods: Using Medicare FFS Identifiable Researc
Autor:
Nina Tunariu, Roberto Alonzi, Holly Tovey, John Staffurth, Helen Stidwill, Matthew D. Blackledge, Alison Tree, Chris Parker, Sophie Perry, Emma Hall, Dow-Mu Koh, Anwar R. Padhani, Peter Chatfield, Jessica Finch
Publikováno v:
Journal of Clinical Oncology. 37:e16513-e16513
e16513 Background: Ra-223 improves overall survival in patients with mCRPC, but is associated with increased risk of fracture when used in combination with abiraterone and prednisolone. We have assessed time to first new fracture in men with mCRPC re
Autor:
W. Kimryn Rathmell, Sarah J. Welsh, Vivek Narayan, Ramaprasad Srinivasan, Benjamin L. Maughan, Stéphane Oudard, W. Marston Linehan, Othon Iliopoulos, Tobias Else, Eric Kristopher Park, Jodi K. Maranchie, Eric Jonasch, Frede Donskov, Rodolfo F. Perini, Sanjay Thamake
Publikováno v:
Journal of Clinical Oncology. 39:333-333
333 Background: Patients (pts) with VHL disease are at risk of developing benign and malignant tumors, including ccRCC, pancreatic lesions tumors, CNS hemangioblastomas, and retinal lesions. Inactivation of VHL leads to stabilization of HIF-2α, whic
Autor:
Siddharth A. Padia, Riad Salem, Vivian Bishay, Guy E. Johnson, Ahsun Riaz, Robert J. Lewandowski, Edward Kim
Publikováno v:
Journal of Clinical Oncology. 39:300-300
300 Background: The objective of the LEGACY study was to assess the Objective Response Rate (ORR) and Duration of Response (DoR) following treatment with Yttrium-90 (Y90) glass microspheres in patients with unresectable solitary hepatocellular carcin
Autor:
Vassiliki Karantza, Jin Seok Ahn, Peter Schmid, Aditya Bardia, Shigehira Saji, Nadia Harbeck, Li Fan, Hope S. Rugo, David W. Cescon, Fabrice Andre, Rita Nanda, Jaime Mejia, Antonio Llombart-Cussac, Mark E. Robson
Publikováno v:
Journal of Clinical Oncology. 38:TPS596-TPS596
TPS596 Background: Combination therapy with immunotherapy + chemotherapy is a promising approach for first-line (1L) treatment of locally recurrent, inoperable TNBC or metastatic TNBC (mTNBC). However, an unmet need exists for effective and tolerable
Autor:
Mary Harlow Garfield, Ronald Peck, Daniel P. Petrylak, Marcia Dougan Moore, Xin Gao, Ian Taylor, Howard A. Burris, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 38:3500-3500
3500 Background: Proteolysis Targeting Chimera (PROTAC) protein degraders induce selective degradation of targeted proteins by engaging the ubiquitin proteasome system. ARV-110 is an orally bioavailable PROTAC that specifically degrades AR ≥ 95% an
Autor:
Fan Jin, Roni Shapira, Ping Qiu, Mallika Sachdev Dhawan, Douglas A. Levine, Alexander Gozman, Timothy A. Yap, Taofeek K. Owonikoko, Andrew Eugene Hendifar, Miguel Quintela-Fandino, Michele Maio, Sanatan Saraf
Publikováno v:
Journal of Clinical Oncology. 38:TPS3156-TPS3156
TPS3156 Background: The anti-PD-1 antibody pembrolizumab (pembro) has improved clinical outcomes in multiple previously treated advanced solid tumors. The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (ola) has shown antitumor activity as mo
Autor:
Daniel P. Petrylak, Ben Li, Charles Schloss, Josep M. Piulats, Raffaele Ratta, Mostefa Bennamoun, Neal D. Shore, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 38:TPS262-TPS262
TPS262 Background: Docetaxel is an established treatment for pts with mCRPC. Pembro, a PD-1 inhibitor, showed single-agent antitumor activity in mCRPC. In the phase 1b/2 KEYNOTE-365 study (NCT02861573), docetaxel + pembro and prednisone showed activi
Autor:
Christopher J. Hoimes, Emmanuel S. Antonarakis, Helen Wu, Aurelius Omlin, Jeri Kim, Anthony Elliott, Charles Schloss, Scott T. Tagawa, Raymond S. McDermott, Clara Hwang, Julie N. Graff, Ulka N. Vaishampayan, Deepak Kilari, Johann S. de Bono, A.J. ten Tije
Publikováno v:
Journal of Clinical Oncology. 38:15-15
15 Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study. Cohort (C)4 (RECIST-measurable disease) and C5 (bone-predominant disease) consist of chemotherapy-naive patients (pts) with mCRPC treated with enza + pembro after progression wi